Karyotypic abnormalities in myelofibrosis following polycythemia vera

被引:42
作者
Andrieux, J
Demory, JL
Caulier, MT
Agape, P
Wetterwald, M
Bauters, F
Lai, JL
机构
[1] Ctr Hosp Reg & Univ Lille, Hop Jeanne De Flandre, Med Genet Lab, F-59037 Lille, France
[2] INSERM U524, Inst Rech Canc Lille, F-59045 Lille, France
[3] CH St Vincent, Hematol Lab, Lille, France
[4] CHRU Lille, Serv Malad Sang, Lille, France
[5] CH Boulogne Sur Mer, Serv Hematol Clin, Boulogne, France
[6] CH Dunkerque, Hematol Serv, Dunkerque, France
关键词
D O I
10.1016/S0165-4608(02)00678-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polycythemia vera (PV) is a chronic myeloproliferative disease characterized by an increase of total red cell volume; in 10% to 15% of cases, bone marrow fibrosis complicates the course of the disease after several years, resulting in a hematologic picture mimicking myelofibrosis with myelocytic metaplasia (MMM). This condition is known as post polycythemic myelofibrosis (PPMF). Among 30 patients with PPMF followed in Northern France, 27 (90%) expressed one or two abnormal clones in myelocytic cell cultures. Of these, 19 (70%) had partial or complete trisomy 1q. This common anomaly either resulted from unbalanced translocations with acrocentric chromosomes, that is, 1 3 14, and 15, or other chromosomes, that is. 1. 6. 7. 9, 16, 19, and Y, or from partial or total duplication of long arm of chromosome 1. A single patient had an isochromosome 1q leading to tetrasomy 1q. In all cases, a common trisomic region spanning 1q21 to 1q32 has been identified. Given that most patients had previously received chemotherapy or radio-phosphorus to control the polycythemic phase of their disease, this Study illustrates the increased frequency of cytogenetic abnormalities after Such treatments: 90% versus 50% in de novo MMM. Moreover, karyotype can be used to distinguish PPMF-where trisomy 1q is the main anomaly- from primary MMM where trisomy 1q is rare and deletions 13q or 20q are far more common. Whether trisomy 1q is or is not a secondary event remains a matter of debate, as well as the role of cytotoxic treatments. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:118 / 123
页数:6
相关论文
共 19 条
[11]  
2-O
[12]  
Mitelman F., 1995, SUPPLEMENT INT SYSTE
[13]  
RANDI ML, 1994, J MED, V25, P363
[14]   A CHROMOSOMAL PROFILE OF POLYCYTHEMIA-VERA [J].
REGECAMBRIN, G ;
MECUCCI, C ;
TRICOT, G ;
MICHAUX, JL ;
LOUWAGIE, A ;
VANHOVE, W ;
FRANCART, H ;
VANDENBERGHE, H .
CANCER GENETICS AND CYTOGENETICS, 1987, 25 (02) :233-245
[15]   Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases [J].
Reilly, JT ;
Snowden, JA ;
Spearing, RL ;
Fitzgerald, PM ;
Jones, N ;
Watmore, A ;
Potter, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (01) :96-102
[16]   Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea:: High proportion of cases with 17p deletion [J].
Sterkers, Y ;
Preudhomme, C ;
Laï, JL ;
Demory, JL ;
Caulier, MT ;
Wattel, E ;
Bordessoule, D ;
Bauters, F ;
Fenaux, P .
BLOOD, 1998, 91 (02) :616-622
[17]  
SWOLIN B, 1988, BLOOD, V72, P386
[18]   Medical progress: Myelofibrosis with myeloid metaplasia. [J].
Tefferi, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (17) :1255-1265
[19]   Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia [J].
Tefferi, A ;
Mesa, RR ;
Schroeder, G ;
Hanson, CA ;
Li, CY ;
Dewald, GW .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) :763-771